Ovarian cancer, version 2.2013: Featured updates to the NCCN guidelines

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 11, Issue 10, 2013, Pages 1199-1209

  Morgan Jr , Robert J ^a   Alvarez, Ronald D ^b   Armstrong, Deborah K ^c   Burger, Robert A ^d   Chen, Lee May ^e   Copeland, Larry ^f   Crispens, Marta Ann ^g   Gershenson, David M ^h   Gray, Heidi J ⁱ   Hakam, Ardeshir ^j   Havrilesky, Laura J ^k   Johnston, Carolyn ^l   Lele, Shashikant ^m   Martin, Lainie ^d   Matulonis, Ursula A ⁿ   O'Malley, David M ^f   Penson, Richard T ^o   Powell, Matthew A ^p   Remmenga, Steven W ^q   Sabbatini, Paul ^r   Santoso, Joseph T ^s   Schink, Julian C ^t   Teng, Nelson ^u   Werner, Theresa L ^v   Dwyer, Mary A ^w   Hughes, Miranda ^w   more..

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d FOX CHASE CANCER CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f OHIO STATE UNIVERSITY   (United States)

^g VANDERBILT INGRAM CANCER CENTER   (United States)

^h UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

ⁱ SEATTLE CANCER CARE ALLIANCE   (United States)

^j H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^k DUKE CANCER INSTITUTE   (United States)

^l UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^m ROSWELL PARK CANCER INSTITUTE   (United States)

ⁿ DANA FARBER BRIGHAM AND WOMEN S CANCER CENTER   (United States)

^o MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^p BARNES JEWISH HOSPITAL   (United States)

^q NEBRASKA MEDICAL CENTER   (United States)

^r MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^s UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^t NORTHWESTERN UNIVERSITY   (United States)

^u STANFORD CANCER INSTITUTE   (United States)

^v UNIVERSITY OF UTAH   (United States)

^w National Comprehensive Cancer Network   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALTRETAMINE; ANASTROZOLE; BEVACIZUMAB; CA 125 ANTIGEN; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; LETROZOLE; LEUPRORELIN; MEGESTROL ACETATE; MELPHALAN; NAVELBINE; OXALIPLATIN; PACLITAXEL; PEMETREXED; TAMOXIFEN; TOPOTECAN;

ABDOMINAL DISCOMFORT; AREA UNDER THE CURVE; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER RECURRENCE; CANCER SCREENING; CANCER SURVIVAL; CATHETER COMPLICATION; CLINICAL DECISION MAKING; CONTINUOUS INFUSION; CYTOREDUCTIVE SURGERY; FATIGUE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; INFECTION; LEUKOPENIA; MIXED MULLERIAN TUMOR; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUROTOXICITY; OVARY CANCER; OVARY CARCINOMA; OVARY TUMOR; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PROFESSIONAL PRACTICE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESIDUAL VOLUME;

FEMALE; HUMANS; OVARIAN NEOPLASMS; RECURRENCE;

EID: 84887254206     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2013.0142     Document Type: Article

References (68)

1. Morgan RJ J.r., Alvarez RD, Armstrong D.K., et al Ovarian Cancer, Version 3.2012. J Natl Compr Canc Netw 2012; 10: 1339-1349.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.
3. Prat J. New insights into ovarian cancer pathology. Ann Oncol 2012; 23(SUPPL. 10): x111-117.
4. McCluggage WG. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. Pathology 2011; 43: 420-432.
5. Edge SB, Byrd DR, Compton C.C., et al AJCC Cancer Staging Manual, 7th ed. New York, NY: Springer; 2010.
6. Kobel M, Kalloger SE, Huntsman D.G., et al Differences in tumor type in low-stage versus high-stage ovarian carcinomas. Int J Gynecol Pathol 2010; 29: 203-211.
7. Seidman JD, Horkayne-Szakaly I, Haiba M., et al The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol 2004; 23: 41-44.
8. Bristow RE, Tomacruz RS, Armstrong D.K., et al Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002; 20: 1248-1259.
9. Chi DS, Franklin CC, Levine D.A., et al Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach. Gynecol Oncol 2004; 94: 650-654.
10. Elattar A, Bryant A, Winter-Roach BA, et al Optimal primary surgical treatment for advanced epithelial ovarian cancer. Cochrane Database Syst Rev 2011: CD007565.
11. Luyckx M, Leblanc E, Filleron T., et al Maximal cytoreduction in patients with FIGO stage IIIC to stage IV ovarian, fallopian, and peritoneal cancer in day-to-day practice: a retrospective French multicentric study. Int J Gynecol Cancer 2012; 22: 1337-1343.
12. Chang SJ, Bristow RE, Ryu HS Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer. Ann Surg Oncol 2012; 19: 4059-4067.
13. Goff BA. Advanced ovarian cancer: what should be the standard of care? J Gynecol Oncol 2013; 24: 83-91.
14. Cristea M, Han E, Salmon L., Morgan RJ Practical considerations in ovarian cancer chemotherapy. Ther Adv Med Oncol 2010; 2: 175-187.
15. Armstrong DK. New issues in systemic therapy for ovarian cancer. J Natl Compr Canc Netw 2013; 11: 690-693.
16. Armstrong DK, Bundy B, Wenzel L., et al Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006; 354: 34-43.
17. Ozols R.F., Bundy BN, Greer B.E., et al Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003; 21: 3194-3200.
18. Vasey PA, Jayson GC, Gordon A, et al Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 2004; 96: 1682-1691.
19. Katsumata N, Yasuda M, Takahashi F., et al Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 2009; 374: 1331-1338.
20. Markman M, Walker JL Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment. J Clin Oncol 2006; 24: 988-994.
21. Marth C, Walker JL, Barakat R.R., et al Results of the 2006 Innsbruck International Consensus Conference on intraperitoneal chemotherapy in patients with ovarian cancer. Cancer 2007; 109: 645-649.
22. Alberts DS, Liu PY, Hannigan E V, et al Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996; 335: 1950-1955.
23. Markman M, Bundy BN, Alberts D.S., et al Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 2001; 19: 1001-1007.
24. Elit L, Oliver TK, Covens A, et al Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer: a systematic review with metaanalyses. Cancer 2007; 109: 692-702.
25. Kirmani S, Braly PS, McClay E.F., et al A comparison of intravenous versus intraperitoneal chemotherapy for the initial treatment of ovarian cancer. Gynecol Oncol 1994; 54: 338-344.
26. Gadducci A, Carnino F, Chiara S., et al Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest. Gynecol Oncol 2000; 76: 157-162.
27. Fujiwara K, Nagao S, Kigawa J., et al Phase II study of intraperitoneal carboplatin with intravenous paclitaxel in patients with suboptimal residual epithelial ovarian or primary peritoneal cancer: a Sankai Gynecology Cancer Study Group Study. Int J Gynecol Cancer 2009; 19: 834-837.
28. Fujiwara K. Three ongoing intraperitoneal chemotherapy trials in ovarian cancer. J Gynecol Oncol 2012; 23: 75-77.
29. Nagao S, Fujiwara K, Ohishi R., et al Combination chemotherapy of intraperitoneal carboplatin and intravenous paclitaxel in suboptimally debulked epithelial ovarian cancer. Int J Gynecol Cancer 2008; 18: 1210-1214.
30. Fujiwara K, Sakuragi N, Suzuki S., et al First-line intraperitoneal carboplatin-based chemotherapy for 165 patients with epithelial ovarian carcinoma: results of long-term follow-up. Gynecol Oncol 2003; 90: 637-643.
31. Landrum LM, Java J, Mathews C.A., et al Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a Gynecologic Oncology Group study. Gynecol Oncol 2013; 130: 12-18.
32. Jaaback K, Johnson N, Lawrie TA Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev 2011: CD005340.
33. Rowan K. Intraperitoneal therapy for ovarian cancer: why has it not become standard? J Natl Cancer Inst 2009; 101: 775-777.
34. Zeimet AG, Reimer D, Radl A.C., et al Pros and cons of intraperitoneal chemotherapy in the treatment of epithelial ovarian cancer. Anticancer Res 2009; 29: 2803-2808.
35. Gore M, du Bois A, Vergote I. Intraperitoneal chemotherapy in ovarian cancer remains experimental. J Clin Oncol 2006; 24: 4528-4530.
36. Armstrong DK, Brady MF Intraperitoneal therapy for ovarian cancer: a treatment ready for prime time. J Clin Oncol 2006; 24: 4531-4533.
37. Ozols RF, Bookman MA, du Bois A, et al Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous carboplatin and paclitaxel. Gynecol Oncol 2006; 103: 1-6.
38. Walker JL, Armstrong DK, Huang H.Q., et al Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol 2006; 100: 27-32.
39. Markman M. Management of ovarian cancer. An impressive history of improvement in survival and quality of life. Oncology (Williston Park) 2006; 20: 347-354.
40. Wenzel LB, Huang HQ, Armstrong D.K., et al Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007; 25: 437-443.
41. Tummala MK, Alagarsamy S, McGuire WP Intraperitoneal chemotherapy: standard of care for patients with minimal residual stage III ovarian cancer? Expert Rev Anticancer Ther 2008; 8: 1135-1147.
42. Barlin JN, Dao F, Zgheib N.B., et al Progression-free and overall survival of a modified outpatient regimen of primary intravenous/ intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer. Gynecol Oncol 2012; 125: 621-624.
43. Landrum LM, Hyde J Jr, Mannel RS, et al Phase II trial of intraperitoneal cisplatin combined with intravenous paclitaxel in patients with ovarian, primary peritoneal and fallopian tube cancer. Gynecol Oncol 2011; 122: 527-531.
44. Markman M. An update on the use of intraperitoneal chemotherapy in the management of ovarian cancer. Cancer J 2009; 15: 105-109.
45. Schwartz J, Toste B, Dizon DS Chemotherapy toxicity in gynecologic cancer patients with a body surface area (BSA)>2 m2. Gynecol Oncol 2009; 114: 53-56.
46. Griggs JJ, Mangu PB, Anderson H, et al Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2012; 30: 1553-1561.
47. Wright JD, Tian C, Mutch D.G., et al Carboplatin dosing in obese women with ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 2008; 109: 353-358.
48. Hunter RJ, Navo MA, Thaker P.H., et al Dosing chemotherapy in obese patients: actual versus assigned body surface area (BSA). Cancer Treat Rev 2009; 35: 69-78.
49. Tewari D, Java J, Salani R., et al Long-term survival advantage of intraperitoneal chemotherapy treatment in advanced ovarian cancer: an analysis of a Gynecologic Oncology Group ancillary data study (GOG#114/172) [abstract]. Presented at the Society of Gynecologic Oncology Annual Meeting on Women's Cancer; March 9-12, 2013; Los Angeles, CA.
50. Sullivan EJ. Bathing abdomen in chemotherapy gives ovarian cancer patients better chance of survival. Society of Gynecologic Oncology Web site. Available at: https://www.sgo.org/newsroom/newsreleases/ eninchemotherapygivesovariancancerpatientsbetterchanceofsurvival/. Accessed September 6, 2013.
51. Risum S, Hogdall C, Markova E., et al Influence of 2-(18F) fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography on recurrent ovarian cancer diagnosis and on selection of patients for secondary cytoreductive surgery. Int J Gynecol Cancer 2009; 19: 600-604.
52. Fulham MJ, Carter J, Baldey A., et al The impact of PET-CT in suspected recurrent ovarian cancer: a prospective multi-centre study as part of the Australian PET Data Collection Project. Gynecol Oncol 2009; 112: 462-468.
53. Bhosale P, Peungjesada S, Wei W., et al Clinical utility of positron emission tomography/computed tomography in the evaluation of suspected recurrent ovarian cancer in the setting of normal CA-125 levels. Int J Gynecol Cancer 2010; 20: 936-944.
54. Son H, Khan SM, Rahaman J, et al Role of FDG PET/CT in staging of recurrent ovarian cancer. Radiographics 2011; 31: 569-583.
55. Rettenmaier NB, Rettenmaier CR, Wojciechowski T, et al The utility and cost of routine follow-up procedures in the surveillance of ovarian and primary peritoneal carcinoma: a 16-year institutional review. Br J Cancer 2010; 103: 1657-1662.
56. Rustin GJ, van der Burg ME, Griffin CL, et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet 2010; 376: 1155-1163.
57. Rustin G, van der Burg M, Griffin C, et al. Early versus delayed treatment of relapsed ovarian cancer. Lancet 2011; 377: 380-381.
58. Miller RE, Rustin GJ How to follow-up patients with epithelial ovarian cancer. Curr Opin Oncol 2010; 22: 498-502.
59. Markman M, Petersen J, Belland A., Burg K. CA-125 monitoring in ovarian cancer: patient survey responses to the results of the MRC/EORTC CA-125 Surveillance Trial. Oncology 2010; 78: 1-2.
60. Salani R, Backes FJ, Fung M.F., et al Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. Am J Obstet Gynecol 2011; 204: 466-478.
61. Morris RT, Monk BJ Ovarian cancer: relevant therapy, not timing, is paramount. Lancet 2010; 376: 1120-1122.
62. Karam AK, Karlan BY Ovarian cancer: the duplicity of CA125 measurement. Nat Rev Clin Oncol 2010; 7: 335-339.
63. Bast RC Jr. CA 125 and the detection of recurrent ovarian cancer: a reasonably accurate biomarker for a difficult disease. Cancer 2010; 116: 2850-2853.
64. Aghajanian C, Blank S V, Goff BA, et al OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012; 30: 2039-2045.
65. Burger RA, Sill MW, Monk B.J., et al Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007; 25: 5165-5171.
66. Cannistra SA, Matulonis UA, Penson R.T., et al Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007; 25: 5180-5186.
67. Elit L, Hirte H. Palliative systemic therapy for women with recurrent epithelial ovarian cancer: current options. Onco Targets Ther 2013; 6: 107-118.
68. Emile G, Chauvenet L, Tigaud J.M., et al A clinical experience of single agent bevacizumab in relapsing ovarian cancer. Gynecol Oncol 2013; 129: 459-462.